688613.SH
奥精医疗
SSE · Healthcare · Medical - Devices · CN
CNY 15.07
−2.46%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 230.0M | 223.7M | 206.0M | 226.5M | 245.3M |
| Cost of Revenue | 72.5M | 70.1M | 59.6M | 39.2M | 40.8M |
| Gross Profit | 157.5M | 153.6M | 146.4M | 187.2M | 204.5M |
| Operating Expenses | |||||
| R&D Expense | 43.1M | 39.2M | 38.8M | 45.5M | 57.5M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 58.9M | 60.7M | 75.6M | 84.3M | 38.7M |
| Selling & Marketing Expense | 55.7M | 55.7M | 48.0M | 37.7M | 31.3M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 164.8M | 163.0M | 165.6M | 171.2M | 126.4M |
| Cost and Expenses | 237.2M | 233.2M | 225.2M | 210.5M | 167.1M |
| Operating Income (EBIT) | 13.3M | 12.0M | (7.4M) | 49.0M | 96.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 13.6M | 12.3M | (8.9M) | 49.1M | 96.2M |
| Income Tax Expense | 3.4M | 2.8M | 8.2M | (3.9M) | 4.5M |
| Bottom Line | |||||
| Net Income | 14.2M | 13.8M | (12.7M) | 54.2M | 95.2M |
| Earnings from Cont. Ops | 10.2M | 9.5M | (17.1M) | 53.0M | 91.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 14.2M | 13.8M | (12.7M) | 54.2M | 95.2M |
| Per Share | |||||
| Basic EPS | CN¥0.10 | CN¥0.10 | (CN¥0.09) | CN¥0.41 | CN¥0.71 |
| Diluted EPS | CN¥0.10 | CN¥0.10 | (CN¥0.09) | CN¥0.41 | CN¥0.71 |
| Revenue Per Share | CN¥1.63 | CN¥1.62 | CN¥1.46 | CN¥1.71 | CN¥1.83 |
| Shares | |||||
| Basic Shares Outstanding | 141.1M | 138.4M | 140.7M | 132.3M | 134.1M |
| Diluted Shares Outstanding | 141.1M | 138.4M | 140.7M | 132.3M | 134.1M |
| Profitability Metrics | |||||
| EBITDA | — | 41.6M | 16.1M | 68.7M | 112.8M |
| D&A | — | 29.6M | 23.5M | 19.7M | 16.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026